




UNITED STATES PATENT AND TRADEMARK OFFICE



COPY 12516-US

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

U.S. APPLICATION NUMBER NO. ✓ 10/552,327	FIRST NAMED APPLICANT Ee Chee Ren	ATTY. DOCKET NO. ✓ 22516-US
---	--------------------------------------	--------------------------------

22829
 ROCHE MOLECULAR SYSTEMS INC
 PATENT LAW DEPARTMENT
 1145 ATLANTIC AVENUE
 ALAMEDA, CA 94501



INTERNATIONAL APPLICATION NO. PCT/SG04/00103	
I.A. FILING DATE 04/21/2004	PRIORITY DATE 04/21/2003

CONFIRMATION NO. 8907
 371 FORMALITIES LETTER



OC000000019636914

Date Mailed: 07/17/2006

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patent Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patent Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed

to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

CHARITTA A BURT

Telephone: (703) 308-9140 EXT 207

PART 1 - ATTORNEY/APPLICANT COPY


U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/552,327	PCT/SG04/00103	22516-US

FORM PCT/DO/EO/922 (371 Formalities Notice)

COPY

ROCHE MOLECULAR SYSTEMS	
File No.	22516-US 5
Date/By	7-26-06
Attorney	BAP / HIL
Action	Seq Listings
Due Date	9/17/06
Final Date	1/17/07

CERTIFICATE OF MAILING (37 CFR 1.8a)



I hereby certify that this paper (along with any paper referred to as being transmitted therewith) is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Sequence, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on:

Date:

8-1-06

By:

Winsome St. Rose

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

EE Chen Ren, et al.

SERIAL NO.: 10/552,327

INTERNATIONAL FILING DATE: APRIL 21, 2004

FOR: REAGENTS AND METHODS FOR
DETECTING SEVERE ACUTE
RESPIRATORY SYNDROME
CORONAVIRUS

)

) EXAMINER: N/A

) ART UNIT: N/A

) Confirmation No. N/A

) DOCKET NO 22516-US5

RESPONSE TO NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT
APPLICATIONS CONTAINING NUCLEOTIDE AND /OR AMINO ACID SEQUENCES
DISCLOSURES

Mail Stop Sequence
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Notification to Comply With Requirements for Patent Applications
Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures of Application
mailed July 17, 2006, applicants hereby submit the following:

- ☒ Copy of the Notification to Comply mailed July 17, 2006.
- ☒ Statement Under 37 C.F.R. § 1.821, and
- ☒ CRF and Paper copies of the Sequence Listings.

Respectfully submitted,

Date:

August 1, 2006

Christopher C. Sappenfield
Reg. No. 45,073

ROCHE MOLECULAR SYSTEMS, INC.
1145 Atlantic Avenue
Alameda, CA 94501
Tele: 510-814-2800
Fax: 510-814-2973
Customer No. 22829